David Thomas

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. doi request reprint Global control of hepatitis C: where challenge meets opportunity
    David L Thomas
    Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Nat Med 19:850-8. 2013
  2. doi request reprint New challenges in viral hepatitis
    David Thomas
    Division of Infectious Diseases, Johns Hopkins School of Medicine, Suite 437, 1830 Monument Street, Baltimore, MD 21205, USA
    Gut 61:i1-5. 2012
  3. pmc Hepatitis C in HIV-infected individuals: cure and control, right now
    David L Thomas
    Johns Hopkins School of Medicine, Baltimore, USA
    J Int AIDS Soc 14:22. 2011
  4. ncbi request reprint Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland
    Danielle C Ompad
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Clin Infect Dis 35:783-8. 2002
  5. pmc Methylation regulates hepatitis B viral protein expression
    Perumal Vivekanandan
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Infect Dis 199:1286-91. 2009
  6. ncbi request reprint Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial
    Richard D Semba
    Department of Ophthalmology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 45:298-303. 2007
  7. pmc Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells
    Minkyung Yi
    Center for Hepatitis Research, Institute for Human Infections and Immunity, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555 1019, USA
    Proc Natl Acad Sci U S A 103:2310-5. 2006
  8. ncbi request reprint Progression of liver fibrosis among injection drug users with chronic hepatitis C
    Lucy E Wilson
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1002, USA
    Hepatology 43:788-95. 2006
  9. ncbi request reprint Identification of a specific gene expression pattern associated with HCV-induced pathogenesis in HCV- and HCV/HIV-infected individuals
    Kathie Anne Walters
    Department of Microbiology, School of Medicine, University of Washington, Box 358070, Seattle, WA 98195 8070, USA
    Virology 350:453-64. 2006
  10. ncbi request reprint Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users
    Dawn A Fishbein
    Department of Medicine, Mount Sinai School of Medicine, New, York, NY 10029, USA
    J Acquir Immune Defic Syndr 41:471-6. 2006

Research Grants

  1. HIV HCV Coinfection Antiviral Therapy and Fibrosis
    David Thomas; Fiscal Year: 2007
  2. The Progression of Hepatitis C Among IDUs
    David Thomas; Fiscal Year: 2006
  3. CLINICAL CORE
    David Thomas; Fiscal Year: 2005
  4. HEPATITIS C PATHOGENESIS & THE HUMAN GENOME
    David Thomas; Fiscal Year: 2007
  5. The Progression of Hepatitis C Among IDUs
    David Thomas; Fiscal Year: 2007
  6. The Progression of Hepatitis C Among IDUs
    David L Thomas; Fiscal Year: 2010
  7. HIV HCV Coinfection Antiviral Therapy and Fibrosis
    David Thomas; Fiscal Year: 2009
  8. HIV, DRUG USE AND HEPATITIS C PATHOGENESIS
    David Thomas; Fiscal Year: 2002
  9. HEPATITIS C PATHOGENESIS & THE HUMAN GENOME
    David Thomas; Fiscal Year: 2003
  10. HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS
    David Thomas; Fiscal Year: 2004

Collaborators

Detail Information

Publications68

  1. doi request reprint Global control of hepatitis C: where challenge meets opportunity
    David L Thomas
    Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Nat Med 19:850-8. 2013
    ..How the story ends will largely be determined by the extent to which these rapidly advancing opportunities overcome the growing challenges and by the vigor of the public health response...
  2. doi request reprint New challenges in viral hepatitis
    David Thomas
    Division of Infectious Diseases, Johns Hopkins School of Medicine, Suite 437, 1830 Monument Street, Baltimore, MD 21205, USA
    Gut 61:i1-5. 2012
    ..Nonetheless, important challenges remain. This supplement to Gut looks forward to the next generation of challenges in the field of viral hepatitis, and this introductory article highlights several key issues...
  3. pmc Hepatitis C in HIV-infected individuals: cure and control, right now
    David L Thomas
    Johns Hopkins School of Medicine, Baltimore, USA
    J Int AIDS Soc 14:22. 2011
    ..Thus, HCV is an eradicable disease. There are significant inequalities worldwide in HCV control that could markedly constrain the impact of these measures...
  4. ncbi request reprint Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland
    Danielle C Ompad
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Clin Infect Dis 35:783-8. 2002
    ....
  5. pmc Methylation regulates hepatitis B viral protein expression
    Perumal Vivekanandan
    Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Infect Dis 199:1286-91. 2009
    ..However, data are lacking about whether methylation regulates viral gene expression...
  6. ncbi request reprint Effect of micronutrients and iron supplementation on hemoglobin, iron status, and plasma hepatitis C and HIV RNA levels in female injection drug users: a controlled clinical trial
    Richard D Semba
    Department of Ophthalmology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 45:298-303. 2007
    ..Iron deficiency is common among female injection drug users, but it is unclear whether iron supplementation can reduce anemia and improve iron status without increasing plasma hepatitis C virus (HCV) or HIV RNA levels...
  7. pmc Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells
    Minkyung Yi
    Center for Hepatitis Research, Institute for Human Infections and Immunity, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555 1019, USA
    Proc Natl Acad Sci U S A 103:2310-5. 2006
    ..The ability of this genotype 1a virus to infect cultured cells will substantially benefit antiviral and vaccine discovery programs...
  8. ncbi request reprint Progression of liver fibrosis among injection drug users with chronic hepatitis C
    Lucy E Wilson
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21231 1002, USA
    Hepatology 43:788-95. 2006
    ..In this setting with low fibrosis prevalence, FibroSURE, ALT, and APRI tests predict insignificant fibrosis; however, further work is needed to find noninvasive markers of significant liver fibrosis...
  9. ncbi request reprint Identification of a specific gene expression pattern associated with HCV-induced pathogenesis in HCV- and HCV/HIV-infected individuals
    Kathie Anne Walters
    Department of Microbiology, School of Medicine, University of Washington, Box 358070, Seattle, WA 98195 8070, USA
    Virology 350:453-64. 2006
    ..Importantly, the pattern of gene expression observed in EGE (+) patients has similarities to patients who developed fibrosis within 1 year of receiving a liver transplant...
  10. ncbi request reprint Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users
    Dawn A Fishbein
    Department of Medicine, Mount Sinai School of Medicine, New, York, NY 10029, USA
    J Acquir Immune Defic Syndr 41:471-6. 2006
    ..The predictors of higher HCV RNA levels found in this longitudinal study are consistent with those of prior cross-sectional studies. Further studies are warranted to determine if treatment of alcohol use affects HCV RNA levels...
  11. ncbi request reprint Growing importance of liver disease in HIV-infected persons
    David L Thomas
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Hepatology 43:S221-9. 2006
    ..This review focuses on liver disease in HIV-infected persons, caused by hepatitis C virus, hepatitis B virus, or treatment of HIV infection...
  12. ncbi request reprint Serum albumin as a prognostic indicator for HIV disease progression
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland 21205, USA
    AIDS Res Hum Retroviruses 22:14-21. 2006
    ....
  13. ncbi request reprint Options for treatment of hepatitis C in HIV-infected persons
    David L Thomas
    Johns Hopkins School of Medicine, 1503 East Jefferson Street, Baltimore, MD 21231, USA
    J Hepatol 44:S40-3. 2006
    ..Future research must focus both on improving outcomes with currently available medications and rapidly evaluating the safety and efficacy of forthcoming antiviral compounds in HIV/HCV coinfected persons...
  14. ncbi request reprint Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness
    Mark S Sulkowski
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287 0003, USA
    AIDS 19:S8-12. 2005
  15. ncbi request reprint Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    Clin Infect Dis 41:1035-40. 2005
  16. pmc High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities
    Jennifer V Campbell
    HIV AIDS Epidemiology Program, Public Health Seattle and King County, 106 Prefontaine Place South, Seattle, WA 98104, USA
    Drug Alcohol Depend 81:259-65. 2006
    ..These findings underscore the importance of referring HCV-positive persons to effective alcohol treatment programs to reduce future liver damage and improve eligibility for and effectiveness of treatment of HCV...
  17. ncbi request reprint Humoral immune response in acute hepatitis C virus infection
    Dale M Netski
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Clin Infect Dis 41:667-75. 2005
    ..We investigated the specificity, titer, and neutralizing potential of antibody responses to acute infection by examining 12 injection drug users before, during, and after infection...
  18. pmc Mannose binding lectin genotypes influence recovery from hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
    J Virol 79:9192-6. 2005
    ..76; 95% CI, 1.02 to 3.01; P = 0.04). These data are consistent with the hypothesis that functional MBL plays a central role in the pathogenesis of acute hepatitis B...
  19. ncbi request reprint Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
    Richard K Sterling
    Section of Hepatology, Virginia Commonwealth University Health System, Richmond, VA 23298 0341, USA
    Hepatology 43:1317-25. 2006
    ..In conclusion, noninvasive tests can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in the majority of HIV/HCV-coinfected patients...
  20. pmc Genetic protection against hepatitis B virus conferred by CCR5Delta32: Evidence that CCR5 contributes to viral persistence
    Chloe L Thio
    Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Virol 81:441-5. 2007
    ....
  21. ncbi request reprint Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA
    AIDS 20:2361-9. 2006
    ..To evaluate predictors and trends of referral for hepatitis C virus (HCV) care, clinic attendance and treatment in an urban HIV clinic...
  22. doi request reprint Detection of liver disease in injection drug users
    David L Thomas
    Department of Medicine, Johns Hopkins School of Medicine, 1503 East Jefferson Street, Baltimore, MD 21231, USA
    J Addict Dis 27:19-24. 2008
    ....
  23. pmc Evaluation of IL10, IL19 and IL20 gene polymorphisms and chronic hepatitis B infection outcome
    Ann L Truelove
    Laboratory of Genomic Diversity, National Cancer Institute, Frederick, MD, USA
    Int J Immunogenet 35:255-64. 2008
    ..01-0.04). These results suggest that IL10 and IL20 gene variants influence HBV infection outcome and encourage the pursuit of further studies of these cytokines in HBV pathogenesis...
  24. pmc Human immunodeficiency virus-related microbial translocation and progression of hepatitis C
    Ashwin Balagopal
    Division of Infectious Diseases, Viral Hepatitis Center, Department of Medicine, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Gastroenterology 135:226-33. 2008
    ..We hypothesized that HIV promotes liver disease by enhancing microbial translocation...
  25. pmc CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load
    Adriana Andrade
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Clin Infect Dis 46:e78-82. 2008
    ..Our data suggest that immune activation can cause CD4(+) T cell depletion even when HIV-1 replication appears to be controlled by host factors...
  26. pmc Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2
    Janardan P Pandey
    Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA
    Hum Immunol 69:158-64. 2008
    ....
  27. pmc Limited uptake of hepatitis C treatment among injection drug users
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Community Health 33:126-33. 2008
    ..Low HCV treatment effectiveness was observed in this IDU population. Comprehensive integrated care strategies that incorporate education, case-management and peer support are needed to improve care and treatment of HCV-infected IDUs...
  28. ncbi request reprint Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults
    Mark S Sulkowski
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 21:2209-16. 2007
    ....
  29. ncbi request reprint Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy
    Moses R Kamya
    Department of Medicine, Makerere University, Kampala, Uganda
    J Acquir Immune Defic Syndr 46:187-93. 2007
    ..We identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART)...
  30. pmc Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis
    John R Ticehurst
    Johns Hopkins Bayview Medical Center Clinical Laboratories and Johns Hopkins Hospital Division of Medical Microbiology, Department of Pathology, Johns Hopkins University, Baltimore, Maryland 21224, USA
    J Clin Microbiol 45:2426-33. 2007
    ..6% of the [HCV RNA](BL) differences between individuals (R(2) = 0.046 for 1,304 patients with HAI scores; 0.043 for all 2,472 patients)...
  31. ncbi request reprint Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection
    Rajesh Kannangai
    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    J Clin Virol 39:101-5. 2007
    ..Given that typical chronic HBV infections often have periodic flairs in viral replication and liver damage, we hypothesized that occult HBV may also have flares in viral replication that are associated with increased liver enzymes...
  32. pmc Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution
    Xiao Hong Wang
    Viral Hepatitis Center, Div of Inf Dis, Department of Medicine, Johns Hopkins University School of Medicine, 1503 E Jefferson Street, Suite 114, Baltimore, MD 21231, USA, and Southwest Hospital, Chongqing, People s Republic of China
    J Virol 81:6513-22. 2007
    ..Thus, in a small but carefully matched cohort we found evidence for rapid neutral evolution of HCV in persons with rapid progression of hepatic fibrosis, suggesting higher turnover of infected cells...
  33. ncbi request reprint CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection
    Dale M Netski
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA
    J Infect Dis 195:857-63. 2007
    ..These disease interactions may result in part from impairment of B cell function, which is CD4(+) T cell dependent...
  34. ncbi request reprint Association of CTLA4 polymorphism with regulatory T cell frequency
    Sowsan F Atabani
    Division of Molecular Immunology, Cincinnati Children s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Eur J Immunol 35:2157-62. 2005
    ..These data implicate CTLA4 in regulatory T cell development, and provide a mechanism to account for the link between polymorphisms at this locus and the biological outcome of adaptive immune responses to self and to pathogens...
  35. pmc Divergent and convergent evolution after a common-source outbreak of hepatitis C virus
    Stuart C Ray
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1753-9. 2005
    ..These data suggest that vaccines for genetically diverse viruses may be more effective if they represent consensus sequence, rather than a human isolate...
  36. pmc Cellular immune selection with hepatitis C virus persistence in humans
    Andrea L Cox
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Exp Med 201:1741-52. 2005
    ..015). These findings reveal two distinct mechanisms of sequence evolution involved in HCV persistence: viral escape from CD8+ T cell responses and optimization of replicative capacity...
  37. ncbi request reprint Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection
    Irene Kuo
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, E6006 Baltimore, MD 21205, USA
    Drug Alcohol Depend 73:69-78. 2004
    ..We examined correlates of HBV infection and vaccination and the missed vaccination opportunities among young injection drug users (IDUs) and non-injection drug users (NIDUs)...
  38. pmc Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Virol 77:12083-7. 2003
    ..The associations with class I alleles are consistent with a previously implicated role for CD8-mediated cytolytic-T-cell response in determining the outcome of an acute HBV infection...
  39. ncbi request reprint The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    J Acquir Immune Defic Syndr 33:577-84. 2003
    ..DESIGN Retrospective cohort analysis of 1230 persons on their first HAART regimen who had at least 1 random glucose measurement before and during antiretroviral therapy...
  40. ncbi request reprint The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users
    Lynne Strasfeld
    Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York 10467, USA
    J Acquir Immune Defic Syndr 33:356-64. 2003
    ..However, a substantial degree of the person-to-person variability in the prevalence and level of detectable HCV RNA remains unexplained...
  41. ncbi request reprint Hepatitis C in the HIV-infected patient
    Mark S Sulkowski
    Viral Hepatitis Section, Division of Infectious Diseases, Johns Hopkins School of Medicine, Suite 102, 424 North Bond Street, Baltimore, MD 21231, USA
    Clin Liver Dis 7:179-94. 2003
    ..Future efforts should include prospective studies that demonstrate the natural history and optimal management of HIV/HCV-coinfected patients, including the feasibility of liver transplantation...
  42. ncbi request reprint Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA
    James J Goedert
    Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892, USA
    AIDS 17:425-33. 2003
    ..We sought to identify risk factors for infection with the Kaposi's Sarcoma-associated herpesvirus (KSHV) among pregnant women and to examine a reported association of KSHV with injecting drug use (IDU) and hepatitis C virus (HCV) infection...
  43. ncbi request reprint HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
    Chloe L Thio
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Lancet 360:1921-6. 2002
    ..Our aim was to examine liver-related mortality among people at risk for HIV-1 and HBV infections...
  44. ncbi request reprint Hepatitis C and human immunodeficiency virus infection
    David L Thomas
    Viral Hepatitis Section, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA
    Hepatology 36:S201-9. 2002
    ..Properly designed studies of therapy in HIV/HCV-coinfected persons are needed to help guide management of these patients in the future...
  45. ncbi request reprint Occult hepatitis B
    Michael Torbenson
    Department of Pathology, Division of Gastrointestinal and Hepatic Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
    Lancet Infect Dis 2:479-86. 2002
    ..Although much more research is needed, existing reports justify a heightened awareness of the medical importance and means of testing for occult hepatitis B...
  46. ncbi request reprint Hepatitis C and progression of HIV disease
    Mark S Sulkowski
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E Monument St, Room 448, Baltimore, MD 21287 0003, USA
    JAMA 288:199-206. 2002
    ..Conflicting reports exist regarding the effect of hepatitis C virus (HCV) on the progression of human immunodeficiency virus (HIV) disease...
  47. ncbi request reprint Protection against persistence of hepatitis C
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, USA
    Lancet 359:1478-83. 2002
    ..However, HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and duration of viraemia with re-challenge. We aimed to establish whether similar immunity could be achieved in man...
  48. ncbi request reprint Needlestick transmission of hepatitis C
    Mark S Sulkowski
    Johns Hopkins School of Medicine, 424 N Bond St, Baltimore, MD 21231, USA
    JAMA 287:2406-13. 2002
    ..These data underscore the importance of identifying persons with acute HCV infection and promptly referring them to experienced clinicians who can provide updated counseling and treatment...
  49. ncbi request reprint Peginterferon-alpha-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open-label study
    Mark Sulkowski
    The Johns Hopkins University School of Medicine, 1830 East Monument Street, Rm 448, Baltimore, MD 21267 0003, USA
    BioDrugs 16:105-9. 2002
    ..We conducted a phase II study to assess the safety and initial efficacy of peginterferon-alpha-2a (40kD) plus ribavirin combination therapy in patients with chronic hepatitis C (CHC)...
  50. ncbi request reprint Severity and correlates of liver disease in hepatitis C virus-infected injection drug users
    Rudra Rai
    Division of Gastroenterology, The Johns Hopkins School of Medicine, Baltimore, MD 21231 1001, USA
    Hepatology 35:1247-55. 2002
    ..In conclusion, these data indicate that severe liver disease is uncommon in this urban, HCV-infected IDU cohort, especially in younger persons and those with repeatedly normal liver enzymes...
  51. ncbi request reprint High prevalence of occult hepatitis B in Baltimore injection drug users
    Michael Torbenson
    Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Hepatology 39:51-7. 2004
    ..20 years). In conclusion, although further research is needed to assess its clinical significance, there is a high prevalence of occult HBV infection in this cohort of HCV-infected injection drug users...
  52. ncbi request reprint Changes in hepatitis B virus DNA levels with acute HIV infection
    Chloe L Thio
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Infect Dis 38:1024-9. 2004
    ..Acute HIV infection is not consistently associated with an increased blood HBV DNA level. Additional research is needed to understand the mechanism for the unexpected reductions in HBV DNA levels associated with acute HIV infection...
  53. pmc Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users
    Dale M Netski
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland
    J Clin Microbiol 42:1631-6. 2004
    ..Reproducibility, low technical requirements, and high throughput should make this assay useful for clinical or research monitoring of HCV levels during active infection...
  54. ncbi request reprint Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index
    Thomas B Kelleher
    Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 8E, Boston, MA 02215, USA
    J Hepatol 43:78-84. 2005
    ..To examine if serum fibrosis biomarkers could accurately identify the stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients...
  55. ncbi request reprint Prospective evaluation of community-acquired acute-phase hepatitis C virus infection
    Andrea L Cox
    Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Clin Infect Dis 40:951-8. 2005
    ....
  56. ncbi request reprint Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus
    Mark S Sulkowski
    Division of Infectious Diseases Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    AIDS 19:585-92. 2005
    ....
  57. ncbi request reprint Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment
    Mark S Sulkowski
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Infect Dis 40:S263-9. 2005
    ..Solutions to the problem of HCV infection among IDUs must account for these facts...
  58. ncbi request reprint Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study
    Ronald C Hershow
    University of Illinois at Chicago School of Public Health, Chicago, IL 60612, USA
    Clin Infect Dis 40:859-67. 2005
    ..The Women and Infants Transmission Study provided an opportunity to assess this issue...
  59. ncbi request reprint Management and treatment of injection drug users with hepatitis C virus (HCV) infection and HCV/human immunodeficiency virus coinfection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia
    Semin Liver Dis 25:18-32. 2005
    ....
  60. ncbi request reprint The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection
    Shruti H Mehta
    Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD 21205 0003, USA
    Hepatology 41:123-31. 2005
    ..Recognition of bridging fibrosis and cirrhosis in some but not most patients underscores the importance of identifying and treating liver disease in HIV/HCV coinfected persons...
  61. ncbi request reprint Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes
    John S Francis
    Division of Infectious Diseases, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Clin Infect Dis 40:100-7. 2005
    ..During a 2-month period in the winter of 2003-2004, four healthy adults presented to 1 of 2 Baltimore hospitals with severe necrotizing MRSA pneumonia in the absence of typical risk factors for MRSA infection...
  62. ncbi request reprint Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir
    Mark S Sulkowski
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    AIDS 18:2277-84. 2004
    ....
  63. ncbi request reprint Prevalence of cryoglobulinemia in hepatitis C virus (HCV) positive patients with and without human immunodeficiency virus (HIV) coinfection
    Charlene S Dezzutti
    Centers for Disease Control and Prevention, Mailstop G19, 1600 Clifton Road, NE, Atlanta, GA 30333, USA
    J Clin Virol 31:210-4. 2004
    ..Coinfection with human immunodeficiency virus (HIV) has been shown to influence the natural history of hepatitis C infection...
  64. pmc Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection
    Chloe L Thio
    Department of Medicine, Johns Hopkins Medical Institutions, 1503 E Jefferson Street, Baltimore, MD 21231, USA
    J Virol 78:11258-62. 2004
    ..32, P = 0.04). These data suggest that CTLA4 influences recovery from HBV infection, which is consistent with the emerging role of T regulatory cells in the pathogenesis of disease...
  65. ncbi request reprint Risk factors for hepatitis C virus infection among blood donors in northern Thailand
    Lakkana Thaikruea
    Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    Transfusion 44:1433-40. 2004
    ..The epidemiology, virology, and risk factors for hepatitis C virus (HCV) infection among blood donors in northern Thailand have not been extensively evaluated...
  66. ncbi request reprint HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection
    Salim I Khakoo
    Liver Group, Division of Infection, Inflammation, and Repair, Southampton University, Southampton 5016 6YD, UK
    Science 305:872-4. 2004
    ..The data strongly suggest that inhibitory NK cell interactions are important in determining antiviral immunity and that diminished inhibitory responses confer protection against HCV...
  67. pmc Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus
    Janardan P Pandey
    Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina 29425 2230, USA
    J Virol 78:4561-5. 2004
    ..Further investigations involving candidate genes (GM, KM, HLA, and Fcgamma receptors) and cellular and humoral immune responses to HCV epitopes are needed to understand the mechanisms underlying these associations...
  68. ncbi request reprint Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections
    Mark S Sulkowski
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD21205, USA
    Hepatology 35:182-9. 2002
    ..Severe hepatotoxicity occurs throughout the course of NNRTI therapy and is more common among patients prescribed nevirapine, those coinfected with HCV or HBV, and those coadministered protease inhibitors...

Research Grants40

  1. HIV HCV Coinfection Antiviral Therapy and Fibrosis
    David Thomas; Fiscal Year: 2007
    ..Afdhal) and metabolic complications of ART (Dr. Powderly) to supplement the strong research environment at Johns Hopkins that has already produced some of the most significant studies on liver disease in this setting. ..
  2. The Progression of Hepatitis C Among IDUs
    David Thomas; Fiscal Year: 2006
    ..A high likelihood of success is anticipated since the work builds on precious existing resources and will be performed by a team of investigators who have already demonstrated the necessary skills. ..
  3. CLINICAL CORE
    David Thomas; Fiscal Year: 2005
    ..By accomplishing these aims, the Clinical Core will make a major contribution to our understanding of hepatitis C recovery and achieve many of the objectives of RFA-AI-04-028. ..
  4. HEPATITIS C PATHOGENESIS & THE HUMAN GENOME
    David Thomas; Fiscal Year: 2007
    ..Given the established collaborative research networks and the power of scientific methods, we anticipate a high likelihood of success. ..
  5. The Progression of Hepatitis C Among IDUs
    David Thomas; Fiscal Year: 2007
    ..success is anticipated in this research program as an experienced, cohesive team will continue to use available technology and well characterized human tissues to understand HCV related liver disease progression in HIV infected persons ..
  6. The Progression of Hepatitis C Among IDUs
    David L Thomas; Fiscal Year: 2010
    ..success is anticipated in this research program as an experienced, cohesive team will continue to use available technology and well characterized human tissues to understand HCV related liver disease progression in HIV infected persons ..
  7. HIV HCV Coinfection Antiviral Therapy and Fibrosis
    David Thomas; Fiscal Year: 2009
    ..Afdhal) and metabolic complications of ART (Dr. Powderly) to supplement the strong research environment at Johns Hopkins that has already produced some of the most significant studies on liver disease in this setting. ..
  8. HIV, DRUG USE AND HEPATITIS C PATHOGENESIS
    David Thomas; Fiscal Year: 2002
    ..Success at minimal expense is likely because the study will utilize a large HCV-infected cohort, an established research setting, eight years of existing data, experienced lab personnel, and superb collaborators. ..
  9. HEPATITIS C PATHOGENESIS & THE HUMAN GENOME
    David Thomas; Fiscal Year: 2003
    ..Success is anticipated at modest expense since experienced researchers will be using existing molecular tools to investigate large established cohorts. ..
  10. HIV HCV COINFECTION--ANTIVIRAL THERAPY AND FIBROSIS
    David Thomas; Fiscal Year: 2004
    ..Given the experience of the investigative team and the extensive preliminary data, we anticipate providing data that will directly affect forthcoming guidelines for the medical management of HIV-HCV coinfected persons. ..
  11. Hepatitis C Pathogenesis and the Human Genome
    David L Thomas; Fiscal Year: 2010
    ..There is a special focus on genes that appear to affect HIV and other chronic viral infections. ..